1. Search Result
Search Result
Results for "

lipid content

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W420337

    LH2010A

    Reactive Oxygen Species (ROS) Infection
    Fluopimomide (LH2010A) is a potent pesticide, widely used for agricultural pest management. Fluopimomide adversely affects the nematodes growth, locomotive behaviors, reproduction, and lifespan, accompanying with enhanced of reactive oxygen species (ROS) generation, lipid and lipofuscin accumulation, and malondialdehyde content. Fluopimomide inhibits antioxidant systems in the nematodes .
    Fluopimomide
  • HY-W250743

    Biochemical Assay Reagents Others
    Cresyl diphenyl phosphate is a compound that disrupts lipid homeostasis in zebrafish embryos, causing alterations in lipid content and lipidomic profiles, as well as affecting gene expression and energy homeostasis. |
    Cresyl diphenyl phosphate
  • HY-158790

    Ferroptosis Cancer
    (R)-HTS-3 is an lysophosphatidylcholine acyltransferase 3 (LPCAT3) inhibitor, with an IC50 of 0.09 μM. (R)-HTS-3 suppresses the C20:4 content of PE, PC, and PS, while promoting a correspondingelevation in C22:4 phospholipids and a paradoxical increase in C20:4 phosphatidylinositol (PI) lipids .
    (R)-HTS-3
  • HY-19796
    Icomidocholic acid
    1 Publications Verification

    Aramchol; C20-FABAC

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
    Icomidocholic acid
  • HY-W269593
    Perfluorodecanoic acid
    1 Publications Verification

    PFDA

    Caspase Interleukin Related Metabolic Disease
    Perfluorodecanoic acid (PFDA) is a perfluoroalkyl substance (PFAS). Perfluorodecanoic acid induces weight loss and increases liver weight and lipid content in mice. Perfluorodecanoic acid also reduces mRNA expression of the genes encoding IL-1β, IL-18, and cellular inhibitor of apoptosis 2 (cIAP2), as well as caspase-1, -3, and -7 in mouse liver .
    Perfluorodecanoic acid
  • HY-D1745

    fac-[Re(CO)3(phen)L]

    Fluorescent Dye Others
    Liptracker-green (fac-[Re(CO)3(phen)L]) is a cell-permeable fluorogenic probe that localizes to polar lipids, and can be used to label lipid droplets and other high lipid-content compartments in live and fixed cells using fluorescent microscopy.
    Liptracker-Green
  • HY-165104

    GuCGp; Gulopyranosyl-(β1-1)-caldarchaetidylglycerol

    Bacterial Others
    β-L-Gulopyranosyl-caldarchaetidyl-glycerol (GuCGp) is a compound that is studied in the polar lipid composition of thermoacidophilic bacteria. Its content varies under different culture conditions, which may be related to the adaptation of bacteria to the environment.
    β-L-Gulopyranosyl-caldarchaetidyl-glycerol
  • HY-B2078

    Neurokinin Receptor Inflammation/Immunology
    Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
    Eprazinone
  • HY-161388

    Ferroptosis Mitophagy Cancer
    NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca 2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent .
    NSCLC-IN-1
  • HY-146398

    AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-176212

    Ferroptosis VDAC Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-20 (Compound 34a) is a Ferroptosis inhibitor (EC50: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe 2+ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI) .
    Ferroptosis-IN-20
  • HY-131688

    PARP Caspase Inflammation/Immunology
    2-Chlorohexadecanoic acid, an inflammatory lipid mediator, interferes with protein palmitoylation,induces ER-stress markers, reduced the ER ATP content, and activates transcription and secretion of IL-6 as well as IL-8.2-Chlorohexadecanoic acid disrupts the mitochondrial membrane potential and induces procaspase-3 and PARP cleavage.2-Chlorohexadecanoic acid can across blood-brain barrier (BBB) and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3 .
    2-Chlorohexadecanoic acid
  • HY-N11507

    TKV

    PPAR Metabolic Disease
    Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .
    Tibesaikosaponin V
  • HY-159595

    LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-174858

    PROTACs ASK1 p38 MAPK Metabolic Disease
    dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH) (Pink: ASK1 ligand 1 (HY-174860); Blue: E3 ligand (S,R,S)-AHPC (HY-125845); Black: Linker, (S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH (HY-174861) .
    dASK1-VHL
  • HY-W127391

    (Rac)-1,2-Didodecanoylglycerol

    Biochemical Assay Reagents Others
    1,2-Dilaurin is a diacylglycerol containing lauric acid at the sn-1 and sn-2 positions. It has been used as an internal standard for the quantification of diglycerides in rat desheathed sciatic nerves. [1] Monomolecular films containing 1,2-dilauroyl-rac-glycerol have been used as substrates to measure surface pressure and the effect of pancreatic procolipase and colipase on porcine pancreatic lipase activity. [2] References: [1]. Zhu, X. and Eichberg, J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in the sciatic nerve of streptozotocin-induced diabetic rats. J. Neurochemistry. 55(3), 1087-1090 (1990).[2]. Wieloch, T., Borgstr m, B., Piéroni, G. et al. Porcine trypsinogen and its trypsin-activated form: lipid binding and lipase activation on monomolecular membranes. FEBS Express. 128(2), 217-220 (1981).
    1,2-Dilaurin
  • HY-D1056E

    LPS, from Pseudomonas aeruginosa (10)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides from P. aeruginosa (Pseudomonas aeruginosa) 10 are lipopolysaccharide endotoxins and TLR4 activators derived from Pseudomonas aeruginosa 10, and are classified as S-type LPS. Lipopolysaccharides from P. aeruginosa 10 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. The lipopolysaccharides of P. aeruginosa 10 have a fatty acid composition distinct from common enterobacteria, an exceptionally high degree of phosphorylation (triphosphate residues have been detected), and a unique outer region of the core oligosaccharide. Additionally, their O-specific side chains are typically rich in novel aminosugars. Lipopolysaccharides from P. aeruginosa 10 demonstrate susceptibility to viruses, with the level of susceptibility determined by the content of high molecular weight polysaccharides in their composition. The absence of high molecular weight polysaccharides increases their sensitivity to bacteriophages .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from P. aeruginosa 10
  • HY-B2167R

    DHA (Standard); Cervonic acid (Standard)

    Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
    Docosahexaenoic acid (Standard)
  • HY-B1018A
    Phenelzine sulfate
    5 Publications Verification

    Monoamine Oxidase GABA Receptor Histone Demethylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
    Phenelzine sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: